Skip to main content
Top
Published in: Drugs & Aging 12/2010

01-12-2010 | Original Research Article

Older Women’s Views about Prescription Osteoporosis Medication

A Cross-Sectional, Qualitative Study

Authors: Dr Kathleen M. Mazor, Sarah Velten, Susan E. Andrade, Robert A. Yood

Published in: Drugs & Aging | Issue 12/2010

Login to get access

Abstract

Background: Osteoporosis is a significant health problem, especially for older women. Prescription osteoporosis medication can reduce fractures, but many women do not accept treatment or discontinue treatment before benefits are achieved.
Objectives: To explore older women’s views about prescription osteoporosis medication use in depth and to identify specific beliefs and experiences that influence these views.
Methods: We conducted in-depth telephone interviews with women aged ≥65 years with clinically confirmed osteoporosis. Interviewees were asked about their beliefs and experiences related to osteoporosis and osteoporosis treatment. Interviews were recorded and transcribed; key themes were identified using qualitative analysis.
Results: Perceived need, medication effectiveness and medication safety were identified as critical influences on women’s views about prescription osteoporosis medication. These perceptions were in turn influenced by various beliefs, experiences and behaviours, including interactions with the physician, personal experience and behaviours, and vicarious experience.
Conclusions: Older women with osteoporosis need clear information about their condition, including the diagnosis, the implications of the diagnosis, treatment options, medication effectiveness and side effects. Physicians should check with their patients to confirm understanding and address concerns, as older women may not always voice their reservations and concerns.
Literature
2.
go back to reference Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009 Feb; 122(2 Suppl.): S3–13PubMedCrossRef Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009 Feb; 122(2 Suppl.): S3–13PubMedCrossRef
3.
go back to reference Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug; 81(8): 1013–22PubMedCrossRef Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug; 81(8): 1013–22PubMedCrossRef
4.
go back to reference Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004 Dec; 15(12): 1003–8PubMedCrossRef Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004 Dec; 15(12): 1003–8PubMedCrossRef
5.
go back to reference Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 Jun; 38(6): 922–8PubMedCrossRef Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 Jun; 38(6): 922–8PubMedCrossRef
6.
go back to reference Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008 Apr; 19(4): 511–7PubMedCrossRef Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008 Apr; 19(4): 511–7PubMedCrossRef
7.
go back to reference Gallagher AM, Rietbrock S, Olson M, et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008 Oct; 23(10): 1569–75PubMedCrossRef Gallagher AM, Rietbrock S, Olson M, et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008 Oct; 23(10): 1569–75PubMedCrossRef
8.
go back to reference Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003 Dec; 14(12): 965–8PubMedCrossRef Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003 Dec; 14(12): 965–8PubMedCrossRef
9.
go back to reference Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008 Nov; 23(11): 1815–21PubMedCrossRef Yood RA, Mazor KM, Andrade SE, et al. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008 Nov; 23(11): 1815–21PubMedCrossRef
10.
go back to reference Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005 Nov 14; 165(20): 2414–9PubMedCrossRef Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005 Nov 14; 165(20): 2414–9PubMedCrossRef
11.
go back to reference Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24(1): 37–55PubMedCrossRef Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24(1): 37–55PubMedCrossRef
12.
go back to reference Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003 Aug; 115(3): 209–16PubMedCrossRef Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003 Aug; 115(3): 209–16PubMedCrossRef
13.
go back to reference McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 Jul; 48(3): 271–87PubMedCrossRef McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 Jul; 48(3): 271–87PubMedCrossRef
14.
go back to reference Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone 2007 Nov; 41(5): 882–7PubMedCrossRef Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone 2007 Nov; 41(5): 882–7PubMedCrossRef
15.
go back to reference Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008 Oct; 19(10): 1421–9PubMedCrossRef Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008 Oct; 19(10): 1421–9PubMedCrossRef
16.
go back to reference Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005 Jan–Jun; Suppl. Web Exclusives: W5-152-W5-66 Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005 Jan–Jun; Suppl. Web Exclusives: W5-152-W5-66
17.
go back to reference McHorney CA, Schousboe JT, Cline RR, et al. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007 Dec; 23(12): 3137–52PubMedCrossRef McHorney CA, Schousboe JT, Cline RR, et al. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 2007 Dec; 23(12): 3137–52PubMedCrossRef
18.
go back to reference Johnson MJ. The medication adherence model: a guide for assessing medication taking. Res Theory Nurs Pract 2002 Fall; 16(3): 179–92PubMedCrossRef Johnson MJ. The medication adherence model: a guide for assessing medication taking. Res Theory Nurs Pract 2002 Fall; 16(3): 179–92PubMedCrossRef
19.
go back to reference Janz N, Champion V, Strecher V. The health belief model. In: Glanz K, Rimer B, Lewis F, editors. Health behavior and health education. 3rd ed. San Francisco (CA): Jossey-Bass, 2002: 45–66 Janz N, Champion V, Strecher V. The health belief model. In: Glanz K, Rimer B, Lewis F, editors. Health behavior and health education. 3rd ed. San Francisco (CA): Jossey-Bass, 2002: 45–66
Metadata
Title
Older Women’s Views about Prescription Osteoporosis Medication
A Cross-Sectional, Qualitative Study
Authors
Dr Kathleen M. Mazor
Sarah Velten
Susan E. Andrade
Robert A. Yood
Publication date
01-12-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11584790-000000000-00000

Other articles of this Issue 12/2010

Drugs & Aging 12/2010 Go to the issue

Acknowledgments

Acknowledgement

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.